The FDA has approved Reyvow for the acute treatment of migraine with or without aura in adults.
Researchers found data that suggest in older patients who were hospitalized with migraines there is not at an increased risk for venous thromboembolism.
Researchers found data that showed medication overuse headache is more likely to occur in certain populations, and to be categorized more frequently according to some international classification guidelines than others.
Researchers found data that showed despite the short half-life of calcitonin gene-related peptide levels found in tears, levels were significantly increased in patients with interictal migraine and unmedicated ictal migraine.
Researchers found data that showed avoiding exercise because of anxiety that it is a trigger in migraine can be addressed by gradual exposure to help with desensitization.
Researchers found data that showed for therapeutic treatment anxiety and sensitivity should be targeted in women patients with migraines.
Researchers found data that showed the efficacy of using burst occipital nerve stimulation in chronic headache.
Treatment with lasmiditan was found to be associated with higher rates of freedom from pain and total migraine freedom compared with placebo in patients with migraine.
Fremanezumab, administered once monthly or once quarterly, is associated with greater reductions in monthly average migraine days than placebo in patients with difficult-to-treat migraine who did not respond to ≥2 of 4 classes of migraine preventative medications.
Lipophilic angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may effectively reduce migraine frequency.